


We claim:

DEAV2003/0016

Dr.WI

1. A compound of the formula I



5

wherein

10 ring A is (C3-C8)-cycloalkanediyl or (C3-C8)-cycloalkenediyl, wherein one or more carbon atoms in said (C3-C8)-cycloalkanediyl and (C3-C8)-cycloalkenediyl groups are optionally replaced by oxygen atoms;

15 R is NR<sub>1</sub>R<sub>2</sub> or OR<sub>1</sub>, (C6-C10)-aryl or (C5-C12)-heteroaryl, wherein said (C5-C12)-heteroaryl group contains one, two or three identical or different heteroatoms selected from the group consisting of N, O and S;

20 R<sub>1</sub>, R<sub>2</sub> are each independently H, (C1-C6)-alkyl, (C3-C8)-cycloalkyl or (C6-C10)-aryl, wherein said (C6-C10)-aryl is optionally substituted by F, Cl or (C1-C4)-alkyl;

25 R<sub>3</sub> is (C3-C6)-cycloalkyl or (C1-C10)-alkyl, wherein each group is optionally substituted by phenyl, pyridyl, morpholinyl or (C3-C6)-cycloalkyl, and wherein said phenyl substituent is optionally substituted by chlorine or (C1-C4)-alkyl;

X is (C1-C6)-alkanediyl, wherein one or more carbon atoms therein are optionally replaced by oxygen atoms;

30 Y is (C1-C6)-alkanediyl, wherein one or more carbon atoms therein are optionally replaced by oxygen atoms;

R<sub>4</sub> is H or (C1-C4)-alkyl;

R5 is (C1-C4)-alkyl;

and pharmaceutically acceptable salts thereof.

5 2. The compound of Claim 1 wherein:

ring A is (C3-C8)-cycloalkane-1,3-diyl or (C3-C8)-cycloalkene-1,3-diyl;

R is NR<sub>1</sub>R<sub>2</sub> or (C6-C10)-aryl;

10

R<sub>1</sub>, R<sub>2</sub> are each independently H, (C1-C6)-alkyl, (C3-C8)-cycloalkyl or (C6-C10)-aryl, wherein said (C6-C10)-aryl group is optionally substituted by F, Cl or (C1-C4)-alkyl;

15 R<sub>3</sub> is (C3-C6)-cycloalkyl or (C1-C8)-alkyl, wherein each group is optionally substituted by phenyl, pyridyl, morpholinyl, (C3-C6)-cycloalkyl, and wherein said phenyl substituent is optionally substituted by chlorine or methyl;

20 X is (C1-C3)-alkanediyl, wherein one carbon atom therein is optionally replaced by an oxygen atom;

Y is (C1-C3)-alkanediyl, wherein the carbon atom adjacent to ring A in said (C1-C3)-alkanediyl group is optionally replaced by an oxygen atom;

25

R<sub>4</sub> is H;

R<sub>5</sub> is methyl;

30

and pharmaceutically acceptable salts thereof.

3. The compound of Claim 2 wherein:

35 ring A is cyclohexane-1,3-diyl;

R is NR<sub>1</sub>R<sub>2</sub> or phenyl;

R<sub>1</sub> is H;

- R2 is (C1-C6)-alkyl, cyclohexyl or phenyl, wherein said phenyl group is optionally substituted by F, Cl or (C1-C4)-alkyl;
- 5 R3 is (C3-C6)-cycloalkyl or (C1-C8)-alkyl, each of which is optionally substituted by phenyl, pyridyl, morpholinyl, cyclopropyl, cyclopentyl, cyclohexyl, and wherein said phenyl substituent is optionally substituted by chlorine or methyl;
- 10 X is O-CH<sub>2</sub>-CH<sub>2</sub>;
- Y is OCH<sub>2</sub>;
- R4 is H;
- 15 R5 is methyl;
- and pharmaceutically acceptable salts thereof.

20 4. The compound of Claim 3 wherein:

- ring A is cyclohexane-1,3-diyl;
- R is NR<sub>1</sub>R<sub>2</sub> or phenyl;
- 25 R<sub>1</sub> is H;
- R<sub>2</sub> is (C1-C4)-alkyl, cyclohexyl or phenyl, wherein said phenyl group is optionally substituted by F, Cl or methyl;
- 30 R<sub>3</sub> is (C3-C6)-cycloalkyl or (C1-C8)-alkyl, each of which is optionally substituted by phenyl, pyridyl, morpholinyl, cyclopropyl, cyclopentyl or cyclohexyl, and wherein said phenyl substituent is optionally substituted by chlorine or methyl;
- 35 X is O-CH<sub>2</sub>-CH<sub>2</sub>;
- Y is OCH<sub>2</sub>;

R4 is H;

R5 is methyl;

5

and pharmaceutically acceptable salts thereof.

5. The compound of Claim 4 wherein the link of X and Y to ring A is cis-configured.

10

6. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds of Claim 1.

7. The pharmaceutical composition of Claim 8 further comprising at least one additional active ingredient.

15

8. The pharmaceutical composition of Claim 7 wherein said additional active ingredient has favorable effects on metabolic disturbances or disorders.

20

9. The pharmaceutical composition of Claim 7 wherein said additional active ingredient is an antidiabetic.

10. The pharmaceutical composition of Claim 7 wherein said additional active ingredient is a lipid modulator.

25

11. A method of treating disorders of fatty acid metabolism and glucose utilization comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

30

12. A method of treating disorders of insulin resistance comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

13. A method of treating diabetes mellitus including the prevention of the sequelae associated therewith comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.
- 5 14. A method of treating dyslipidemia and sequelae associated therewith comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.
- 10 15. A method of treating metabolic syndrome and conditions associated therewith comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.
- 15 16. A method of treating disorders of fatty acid metabolism and glucose utilization comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1 in combination with at least one further active compound.
- 20 17. A method of treating disorders of insulin resistance comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1 in combination with at least one further active compound.